Conclusion: Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.
PubMed 39719170 ↗GLP-1
The short answer. There isn't much data on GLP-1 yet — 28 mentions, 14 with a clear outcome — so treat these numbers as anecdotal. It is most often used for weight loss: 100% of 6 reports say that improved. It is well studied — 1,037 meta-analyses on PubMed.
From 28 mentions in total — the rest didn't say how it went and aren't counted.
What GLP-1 does, according to users
Of the people who reported each effect, the share who said it got better.
7 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 1,037 meta-analyses on PubMed ↗ · 1,604 randomized trials ↗
Conclusion: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes.
PubMed 31422062 ↗Conclusion: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
PubMed 39841962 ↗Conclusion: In this systematic review and meta-analysis of 18 trials, GLP-1 RAs significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with T2D or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although GI AEs warrant attention in long-term management.
PubMed 40952752 ↗2,150 human trials on ClinicalTrials.gov test GLP-1 — 1,220 completed, 307 recruiting now. See all on ClinicalTrials.gov ↗
- Evaluation of a Nutritional Intervention With Dietary Supplements in People Who Have Recently Lost Weight: Effects on Body Composition, Emotional Health, and Gut Microbiota · GLP-1, Weight Loss Trajectory · 2025
- Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists · glp1 Agonist, Gene Expression · 2026
- The Role of Phosphodiesterase Inhibitors in Incretin Secretion · Healthy Volunteers · 2016
Reports to the FDA
Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.
15 reports name a product containing GLP-1 (2024–2026); 12 involved hospitalization or worse. Most often reported:
- Hospitalisation · 3
- Diarrhoea · 2
- Appendicitis · 2
- Diverticulitis · 2
- Abdominal pain upper · 2
- Renal injury · 1
A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I felt better, for certain. Think the insulin clearing the excess sugar's really imrove your well being.”
“I have taken GLP1 but gained a tolerance and decided to stop.”
“When I took a GLP-1 drug, my ADHD improved more significantly than Strattera”
“Together with a GLP-1 it’s got me feeling better than ever.”
Top discussions (5)
- Belly Fat, Not Age, May Be The Bigger Driver of Low Testosterone ↗
- The brain aged more slowly in monkeys given a cheap diabetes drug. Daily dose of the common medication metformin preserved cognition and delayed decline of some tissues. ↗
- I cum very quickly during sex. Need advice. ↗
- This will sound crazy but supplementing high amount of fiber has been nearly equivalent as a GLP1 in benefits for me ↗
- GHK-CU: Amazing! ↗
GLP-1 compared
Other options for weight loss
Sources
- User reports: 28 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- US Food and Drug Administration: CAERS adverse-event reports ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate